The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by el-Zaatari, F. A.
Right arrow Articles by Taurog, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by el-Zaatari, F. A.
Right arrow Articles by Taurog, J. D.

The Journal of Immunology, Vol 144, Issue 4 1512-1517, Copyright © 1990 by American Association of Immunologists


ARTICLES

In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain

FA el-Zaatari, KC Sams and JD Taurog
Harold C. Simmons Arthritis Research Center, University of Texas Southwestern Medical Center, Dallas 75235.

The class I MHC molecule HLA-B27 bears an unpaired Cys residue at position 67, which is predicted to face the Ag binding pocket, based on the x-ray crystallographic model of HLA-A2. To investigate the potential of this residue in the antigenic structure of HLA-B27, a panel of 11 mutant HLA-B27 genes has been created, each bearing a separate amino acid substitution at position 67. The genes were transfected into mouse L cells and the resulting cells analyzed by cytofluorography with a panel of antibodies reactive with the wild-type B27 molecule. Although previous studies had indicated that all mAb that bound the B27 molecule on human lymphocytes bound comparably to L cells transfected with the wild-type B27 gene in the absence of h beta 2-m (human beta 2-microglobulin), the first of the mutant B27 genes was found to express several mAb epitopes in the presence but not in the absence of a h beta 2-m gene. Therefore, subsequent analysis of the B27 mutant panel was conducted in L cells coexpressing the h beta 2-m gene. Under these circumstances, all of the mutants bound the monomorphic anti-class I HLA mAb W6/32 and B.9.12.1, as well as the broadly polymorphic mAb B.1.23.2. Binding to the mutant transfectants of three anti-B27 mAb that cross-react with HLA-B7, ME1, GS145.2, and GSP5.3, was directly proportional to the size of the substituted amino acid side chain. The binding of another anti-B27 mAb, B27M2, that recognizes a B27 determinant that includes the region of amino acids 77-81, was not affected by the Cys67- greater than Tyr67 substitution. Rabbit antibodies to a synthetic peptide composed of B27 amino acids 61-84 bound to both the wild-type B27 and to the Tyr67 mutant. This binding, but not the binding of ME1 or B27M2, was inhibited by the synthetic peptide. These data are interpreted as suggesting that the large amino acid substitutions at position 67 induce a limited conformational change that disrupts the epitopes of the three anti-B27, B7 mAb, that are themselves at least partially conformational. The potential implications of these findings for the role of HLA-B27 in disease pathogenesis are discussed.


This article has been cited by other articles:


Home page
J. Immunol.Home page
H. Appel, W. Kuon, M. Kuhne, M. Hulsmeyer, S. Kollnberger, S. Kuhlmann, E. Weiss, M. Zeitz, K. Wucherpfennig, P. Bowness, et al.
The Solvent-Inaccessible Cys67 Residue of HLA-B27 Contributes to T Cell Recognition of HLA-B27/Peptide Complexes
J. Immunol., December 1, 2004; 173(11): 6564 - 6573.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. N. Antoniou, S. Ford, J. D. Taurog, G. W. Butcher, and S. J. Powis
Formation of HLA-B27 Homodimers and Their Relationship to Assembly Kinetics
J. Biol. Chem., March 5, 2004; 279(10): 8895 - 8902.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Roddis, R. W. Carter, M.-Y. Sun, T. Weissensteiner, A. J. McMichael, P. Bowness, and H. C. Bodmer
Fully Functional HLA B27-Restricted CD4+ as well as CD8+ T Cell Responses in TCR Transgenic Mice
J. Immunol., January 1, 2004; 172(1): 155 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. H. Boyle, J. C. Goodall, S. S. Opat, and J. S. H. Gaston
The Recognition of HLA-B27 by Human CD4+ T Lymphocytes
J. Immunol., September 1, 2001; 167(5): 2619 - 2624.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. O. Hochleitner, M. K. Gorny, S. Zolla-Pazner, and K. B. Tomer
Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A
J. Immunol., April 15, 2000; 164(8): 4156 - 4161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. L. Allen, C. A. O'Callaghan, A. J. McMichael, and P. Bowness
Cutting Edge: HLA-B27 Can Form a Novel {beta}2-Microglobulin-Free Heavy Chain Homodimer Structure
J. Immunol., May 1, 1999; 162(9): 5045 - 5048.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Alvarez, M. Marti, J. Vazquez, E. Camafeita, S. Ogueta, and J. A. Lopez de Castro
The Cys-67 Residue of HLA-B27 Influences Cell Surface Stability, Peptide Specificity, and T-cell Antigen Presentation
J. Biol. Chem., December 21, 2001; 276(52): 48740 - 48747.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.